The US generic drugs company Mylan offered $9.9 billon to buy Sweden-based pharma company Meda, whose product portfolio includes specialty products, branded generics and over-the-counter nonprescription products, such as the antiseptic iodopovidone. According to Mylan, Meda’s two largest shareholders, representing about 30% of Meda’s outstanding shares, have accepted the cash-and-stock offer. The transaction is expected to close by the end of the third quarter 2016, subject to regulatory approval. According to the US company, Meda takeover, should boost its profits next year and would allow it to penetrate emerging-market economies such as China, Russia and Mexico, where growth potential is strong.

LEAVE A REPLY

Please enter your comment!
Please enter your name here